Background
Lung cancer is the most deadly cancer in the world with high morbidity and mortality [
1]. Lung cancer is divided into two subtypes of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Non-small cell lung cancer (NSCLC) is the most common subtype, accounting for more than 80% of all lung cancer [
2]. Moreover, the prognosis of NSCLC patients is still poor, with a 5-year survival rate lower than 18% [
3]. Although the research of NSCLC has been made progress in the past, the molecular mechanism of NSCLC still needs to be explored.
Long noncoding RNAs (lncRNAs) are non-protein coding transcripts longer than 200 nucleotides in length [
4]. Increasing evidence has shown that lncRNAs exerted significant regulatory effects on various biological processes and gene expression through multiple mechanisms [
5]. KCNQ1 overlapping transcript 1 (KCNQ1OT1) was involved in the regulation of numerous genes within the kcnq1 domain [
6]. LncRNA KCNQ1OT1 has been reported to play roles in the pathogenesis of various cancer, such as colorectal cancer [
7], breast cancer [
8] and tongue cancer [
9]. In previous studies, KCNQ1OT1 facilitated progression of cholangiocarcinoma (CCA) by sponging miR-140-5p and regulating SOX4 expression [
10]. However, the mechanism of KCNQ1OT1 in NSCLC still needs further research.
MicroRNAs (miRNAs) are non-protein-encoded short noncoding RNAs composed of 18-25 nucleotides. The roles of miRNAs in epigenetic regulation had progressed, in which miRNAs regulated the protein levels of target mRNAs [
11]. A previous study revealed that miR-129-5p was down-regulated, and inhibited cell proliferation and EMT by negatively regulating HMGB1 in gastric cancer [
12]. Moreover, the role of miR-129-5p in NSCLC have also been studied. LncRNA NNT-AS1 was a carcinogen in non-small cell lung cancer (NSCLC), and acted as a competing endogenous RNA (ceRNA) by targeting miR-129-5p in lung cancer [
13]. However, the relationship between KCNQ1OT1 and miR-129-5p in the progression of NSCLC has not been elucidated.
Jagged1 (JAG1) has been reported to play a role in multiple types of cancer [
14]. Previous studies have shown that JAG1 regulated tumor progression, including NSCLC. Tang et al. found that miR-377-3p suppressed cell proliferation and invasion via targeting JAG1 in ovarian cancer [
15]. Wang et al. indicated that miR-26b was a tumor inhibitor through binding to JAG1 in cervical cancer [
16].
In this study, we measured the expression levels of KCNQ1OT1, miR-129-5p and JAG1 in NSCLC tissues and cells. In addition, we explored the potential interactions between KCNQ1OT1 and miR-129-5p or miR-129-5p and JAG1. In conclusion, this study may provide novel therapeutic targets for NSCLC treatment.
Materials and methods
Tissue samples
All NSCLC tissues and the corresponding adjacent normal tissues were obtained from patients who underwent surgical resection at the Guangdong Second Provincial General Hospital. All patients did not undergo treatments prior to surgery. All patients were categorized according to the Eighth Edition of the American Joint Committee on Cancer TNM Staging System for lung cancer. This research was approved by the Ethics Committee of the Guangdong Second Provincial General Hospital, and written informed consent was collected from all participants. All tissue samples were immediately frozen in liquid nitrogen and then stored at − 80 °C until RNA extraction. The clinical characteristics of patients are summarized in Table
1.
Table 1Correlation between KCNQ1OT1 expression and clinical characters in 60 patients with NSCLC
Age | | | | 0.7892 |
≥ 60 | 38 | 18 | 20 | |
< 60 | 22 | 12 | 10 | |
Gender | | | | 0.6042 |
Man | 33 | 18 | 15 | |
Woman | 27 | 12 | 15 | |
Smoking | | | | 0.4118 |
Yes | 40 | 22 | 18 | |
No | 20 | 8 | 12 | |
Histology | | | | 0.2949 |
Adenocarcinoma | 35 | 20 | 15 | |
Squamous carcinoma | 25 | 10 | 15 | |
Stage | | | | 0.0379 |
I + II | 31 | 11 | 20 | |
III + IV | 29 | 19 | 10 | |
Lymph node metastasis | | | | 0.0127 |
Positive | 40 | 25 | 15 | |
Negative | 20 | 5 | 15 | |
Cell culture
Human lung epithelial cell line (BEAS-2B) and the NSCLC cell lines (A549, H1299, H460, H446 and H1975) were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA) and were grown in Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) at 37 °C containing 5% CO2.
Cell transfection
Small interfering RNA (siRNA) against KCNQ1OT1 (si-KCNQ1OT1, 5′-GGUAGAAUAGUUCUGUCUU-3′; si-KCNQ1OT1#2, 5′-GCCAAUAGCAACUGACUAA-3′; si-KCNQ1OT1#3, 5′-GCCACAUCUAACACCUAUA-3′) and the negative control siRNA (si-NC), KCNQ1OT1 overexpression plasmid (pcDNA-KCNQ1OT1) and the control (pcDNA-NC) were purchased from RiboBio (Guangzhou, China). The miR-129-5p mimic and the mimic negative control (NC mimic), miR-129-5p inhibitor and the negative control (NC inhibitor), siRNA against JAG1 (si-JAG1, 5′-GGCCAAGCCUUGUGUAAAU-3′) and the corresponding negative control (si-NC) were synthesized by Genelily BioTech (Shanghai, China). Cells were transfected by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s requirements.
Quantitative real-time PCR
Total RNA was isolated from tissues and cells using TRIzol reagent (Invitrogen) by the protocols of the manufacturer. The first strand cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kits (Thermo Fisher Scientific). The expression levels were detected using SYBR Green Mixture (Takara, Dalian, China). GAPDH or U6 was used as the endogenous control. Primers as follows: KCNQ1OT1 (forward, 5′-AGGGTGACAGTGTTTCATAGGCT-3′; reverse, 5′-GAGGCACATTCATTCGTTGGT-3′), miR-129-5p (forward, 5′-ACCCAGTGCGATTTGTCA-3′; reverse, 5′-ACTGTACTGGAAGATGGACC-3′), JAG1 (forward, 5′-GTCCATGCAGAACGTGAACG-3′; reverse, 5′-GCGGGACTGATACTCCTTGA-3′), GAPDH (forward, 5′-TCGCCAGCCGAGCCACATC-3′; reverse, 5′-CGTTCTCAGCCTTGACGGTGC-3′), U6 (forward, 5′-CGATACAGAGAAGATTAGCATGGC-3′; reverse, 5′-AACGCTTCACGAATTTGCGT-3′).
CCK-8 assay
The viability of cells was detected with Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan). First, 100 µl of cell suspension (1.0 × 105 cells per well) were seeded into 96-well plates and cultured at 37 °C. Then, 10 µl CCK-8 solution was added to each well after incubation for 48 h. After 4 h, the absorbance was read at 450 nm using Microplate Reader (Bio-Rad, Hercules, CA, USA).
Transwell assay
Cell migration and invasion ability were detected using transwell assay. For cell migration, the transfected cells were plated (1.0 × 105 cells per well) in the upper chamber of a 24-well transwell containing 8 μm polycarbonate membrane (Millipore, Billerica, MA, USA). The serum-free DMEM was added into the upper chamber, and DMEM containing 10% FBS as a chemoattractant was added to the lower chamber. Then, cells were cultured for 48 h at 37 °C, and the cells migrated to the lower surface were fixed with methanol and stained with 0.1% crystal violet. At last, the cells were counted with microscopy. For cell invasion, transwell chambers were coated with Matrigel (Millipore), and other experimental procedures were performed as previously described.
Dual-luciferase reporter assay
The putative binding sites of KCNQ1OT1 and miR-129-5p or miR-129-5p and JAG1 were predicted by LncBase Predicted v.2 or StarBase v2.0. The fragments of KCNQ1OT1 containing wild-type (wt) or mutant (mut) binding sites of miR-129-5p were inserted into pGL3 luciferase reporter plasmids (Promega, Madison, WI, USA), and were co-transfected with miR-129-5p mimic or NC mimic into A549 and H460 cells using Lipofectamine 2000 (Invitrogen). In addition, the sequences of JAG1 3′UTR containing wild-type (wt) or mutant (mut) binding sites of miR-129-5p was cloned into pGL3 vectors (Promega). A549 and H460 cells were co-transfected with miR-129-5p mimic or NC mimic and corresponding luciferase reporter vector using Lipofectamine 2000 (Invitrogen). After the transfection for 48 h, Dual-Luciferase Reporter Assay System (Promega) was used for luciferase activity analysis according to the manufacturer’s instructions.
RNA pull-down assay
RNA pull-down assay was performed as previously described [
17]. Biotin-labeled wild-type KCNQ1OT1 (Bio-KCNQ1OT1), mutant KCNQ1OT1 (Bio-KCNQ1OT1-MUT) and the control (Bio-NC) were purchased from RiboBio. Briefly, the biotinylated RNA was incubated with total RNA extracted from A549 and H460 cell lysates overnight at 4 °C. Then, the biotin-coupled RNA complexes were pulled down using M-280 Streptavidin Dynabeads (Invitrogen) at room temperature for 2 h. After RNA isolation, the abundance of miR-129-5p was detected by qRT-PCR.
Western blot assay
After transfection, A549 and H460 cells were harvested and lysed in RIPA lysis buffer (Thermo Fisher Scientific). Total protein was quantified using the BCA Protein Assay Kit (Pierce, Appleton, WI, USA) with the protocols of the manufacturer. Then, the proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). Furthermore, the membranes were blocked by 5% non-fat milk (Nestlé, Shuangcheng, China) for 2 h at 37 °C, and then incubated with primary antibodies against JAG1 (1:2000; Abcam, Cambridge, UK) or GAPDH (1:2000; Abcam) overnight at 4 °C. Subsequently, the membranes were washed three times with TBST and interacted with horseradish peroxidase (HRP)-conjugated secondary antibody (1:4000; Abcam) for 2 h at room temperature. Finally, the protein bands were visualized via enhanced chemiluminescence system (Thermo Fisher Scientific) and quantitated by ImageJ software (National Institutes of Health, Bethesda, MD, USA). GAPDH was regarded as an endogenous reference.
Statistical analysis
All data were displayed as the mean ± standard deviation (SD) from three independent experiments. Differences between the two groups were analyzed by Student’s t test, and multiple groups were analyzed by one-way analysis of variance (one-way ANOVA). Statistical analysis was performed using Graphpad Prism 7.0 software (GraphPad, San Diego, CA, USA). At P-value < 0.05, the difference was considered to be statistically significant.
Discussion
With the great achievements in diagnosis and treatment, the survival time of NSCLC has increased, but the prognosis of NSCLC is still poor [
18]. In recent years, the studies suggested that lncRNAs dysregulation was associated with the progression of cancers, including NSCLC [
19]. To elucidate the molecular mechanism of lncRNAs in the prognosis of NSCLC is meaningful.
Recent studies exhibited that lncRNA KCNQ1OT1 was upregulated in various cancers. A previous study suggested that KCNQ1OT1 facilitated tumor growth by competitively sponging miR‑504 and up-regulating cyclin‑dependent kinase 16 (CDK16) in hepatocellular carcinoma [
20]. A previous research revealed that KCNQ1OT1 was upregulated in early stage lung cancer and was associated with prognosis in LC patients by suppressing cell proliferation [
21]. Furthermore, Dong et al. demonstrated that KCNQ1OT1 was markedly upregulated in NSCLC tissues and cells, and promoted NSCLC cells proliferation, migration, and invasion by regulating the KCNQ1OT1/miR-27b-3p/HSP90AA1 axis [
22]. Consistent with previous study, the level of KCNQ1OT1 in NSCLC tissues and cell lines was dramatically higher than that in non-tumor tissues and cells. These results revealed that KCNQ1OT1 might exhibit vital roles in NSCLC development and progression.
It has been reported that lncRNAs could be used as competitive endogenous RNAs (ceRNAs) [
23]. This study showed that KCNQ1OT1 could competitively bind to miR-129-5p. MiR-129-5p has been reported as an anti-tumor role in many cancers. In ovarian cancer, miR-129-5p was significantly downregulated in OC tissues and cells, and miR-129-5p acting as tumor suppressor inhibited cell proliferation and promoted apoptosis of OC cell by attenuating the effects of PCAT-1 [
24]. In osteosarcomas, MALAT1 increased stem cell-like properties by regulating the expression of RET via sponging miR-129-5p [
25]. Moreover, the effects of miR-129-5p in NSCLC have also been reported. MiR-129-5p suppressed NSCLC stemness and chemoresistance by targeting DLK1 [
26]. In our study, we demonstrated that miR-129-5p was dramatically down-regulated in NSCLC tissues and cells. Meanwhile, miR-129-5p had binding sites with KCNQ1OT1. Inhibition of miR-129-5p could abolish the effects of KCNQ1OT1 knockdown on the progression of NSCLC.
JAG1 is a Notch ligand that plays a vital role in a variety of signaling pathways [
27]. Recent evidence suggests that JAG1 was an oncogene in NSCLC by inducing cell metastasis [
28]. In this study, we found that JAG1 was inhibited by miR-129-5p in NSCLC, and JAG1 knockdown reversed the effects of miR-129-5p inhibition. In short, KCNQ1OT1 regulated JAG1 expression by sponging miR-129-5p in NSCLC cells.
Conclusion
In conclusion, this study suggested that KCNQ1OT1 and JAG1 were upregulated, while miR-129-5p was down-regulated in NSCLC tissues and cells. Knockdown of KCNQ1OT1 significantly inhibited proliferation, migration and invasion of NSCLC cells. Meanwhile, miR-129-5p inhibition reversed the effects of KCNQ1OT1 knockdown on the progression of NSCLC. In a word, we found that KCNQ1OT1 promoted the NSCLC progression by regulating the KCNQ1OT1/miR-129-5p/JAG1 axis, which provides therapeutic targets for NSCLC.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.